David C. Sane, MD

Percutaneous Coronary Intervention and the Management of Acute Coronary Syndromes in Patients With von Willebrand Disease

04/01/2013

David C. Sane , MD;

Sulaiman Rathore , MD;

Dexter Deleon , MD;

Hafsa Akram , MD;

Tim Ball , MD, PhD;

The optimal management of patients with Von Willebrand disease and acute coronary syndrome is complex and presents a therapeutic challenge. We propose that dual-antiplatelet therapy can be used safely in most vWD patients presenting with ACS,...

The optimal management of...

04/01/2013

Journal of Invasive Cardiology

Superior In-Hospital and 30-Day Outcomes with Abciximab Versus Eptifibatide: A Contemporary Analysis of 495 Consecutive Percutan

08/01/2008

Robert J. Applegate , MD;

Sanjay K. Gandhi , MD, PhD;

Michael A. Kutcher , MD, FACC, FSCAI;

Bharathi Upadhya , MD;

David C. Sane , MD;

Efthymios N. Deliargyris , MD;

Over the past decade clinical trials have demonstrated that platelet glycoprotein (GP) IIb/IIIa receptor inhibition dramatically reduces the ischemic complications of percutaneous coronary intervention (PCI).1–6 Currently, there are 3...

Over the past decade clinical...

08/01/2008

Journal of Invasive Cardiology

Differences in Baseline Characteristics and In-hospital Outcomes in Patients with or without Prior Stroke Undergoing Percutaneou

08/01/2008

Michael A. Kutcher , MD, FACC, FSCAI;

Bharathi Upadhya , MD;

David C. Sane , MD;

Efthymios N. Deliargyris , MD;

Robert J. Applegate , MD;

Sanjay K. Gandhi , MD, PhD;

Percutaneous coronary intervention (PCI) is increasingly used in patients with high-risk baseline characteristics.1–4 A prior stroke may identify patients who are at higher risk for post-PCI complications. However, no comparative data exist...

Percutaneous coronary...

08/01/2008

Journal of Invasive Cardiology

PCI with and without Abciximab after Upstream Eptifibatide Use: Outcomes in High-Risk Patients

08/01/2008

Matthew T. Sacrinty , MPH;

Robert J. Applegate , MD;

Talal T. Baki , MD;

William C. Little , MD;

Sanjay K. Gandhi , MD, PhD;

Michael A. Kutcher , MD, FACC, FSCAI;

David C. Sane , MD;

Mark A. Grabarczyk , MD;

Jason E. Goodin , BA;

Sidney Statonk , MD;

Several clinical trials have demonstrated that platelet glycoprotein (GP) IIb/IIIa receptor inhibition reduces the ischemic complications of percutaneous coronary interventions (PCI).1–4 Comparative data between agents, however, are very...

Several clinical trials have...

08/01/2008

Journal of Invasive Cardiology